This compound is an intermediate used in the manufacture of trilaciclib, a pharmaceutical agent. It is a spirocyclic compound containing a chloro-substituted heteroaromatic ring system.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 2170791-57-6
Tert-butyl 4-methylsulfanyl-10-oxospiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate
pharmaceutical intermediate
Benzyl (2S)-2-{8-aminoimidazo[1,5-a]pyrazin-3-yl}pyrrolidine-1-carboxylate
Pharmaceutical intermediate for impurity synthesis
Fmoc-Ile-Aib-OH
Peptide building block for synthesis
((3aS,5R,6S,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(morpholino)methanone
Pharmaceutical intermediate for SGLT2 inhibitors
((((E)-2-((2R,3R,4R,5R)-3-(((2-CYANOETHOXY)(DIISOPROPYLAMINO)PHOSPHINO)OXY)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)-4-METHOXYTETRAHYDROFURAN-2-YL)VINYL)PHOSPHORYL)BIS(OXY))BIS(METHYLENE) BIS(2,2-DIMETHYLPROPANOATE)
nucleoside phosphoramidite for oligonucleotide synthesis
Tert-butyl 8-hydroxy-4-methylsulfanyl-10-oxo-spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate
Pharmaceutical intermediate for kinase inhibitors
Trilaciclib Impurity 36
pharmaceutical intermediate synthesis
Trilaciclib Impurity 3
Pharmaceutical impurity reference standard
tert-butyl 4-chloro-10-oxospiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate
CQUVVQALIRNJQP-UHFFFAOYSA-N
CC(C)(C)OC(=O)N1CC2(CCCCC2)N3C(=CC4=CN=C(N=C43)Cl)C1=O